Dr. Keller PhD is the founder and director of the Institute for Dementia Research and Prevention at the Pennington Biomedical Research Center.  He is a longstanding clinical trialist and pre-clinical researcher with over 20+ year’s experience and over 200 peer-reviewed publications.  He has continually conducted NIH and Pharmaceutical Industry sponsored efforts since 1998 that encompass every aspect of drug development including high throughput screening, development of preclinical models, clinical trial design, and overseeing over 20 clinical trials as a principal investigator. He was a member of the Louisiana State Board of Medical Examiners for Medical Marijuana and the corresponding author for a manuscript outlining the links between patient demographics and medical cannabis recommendations.  In 2022 he and his clinical site were chosen as one of the clinical sites for the LiBBY clinical trial, which is an NIH funded clinical trial focused on examining the effects of THC on agitation in hospice eligible dementia patients, and one of the largest ever THC clinical trials in the USA. In addition, he is a founder and Editor-in-Chief of Cannabis And Psychedelic Science Journal (CAPS Journal). The CAPS Journal launches April 1 2024 and is being done in partnership with MJBiz and Remind Media to expand the pace and impact of peer-reviewed research in the cannabis and psychedelic space.